Three-city CME Meeting Series!
To register, click on the date & location that best fits your schedule. Please note, each session will contain the same presentations and therefore CME credit can only be provided once.
8:00 – 8:30 am Registration & Breakfast
8:30 – 11:45 am CME Activity
With Mid-morning Break
Dates and Locations
- Thyroid Eye Disease: Back to Basics
- Digging Deeper to Improve Differential Diagnosis
- Case Presentation: Differential Diagnosis – Is It Dry Eye or TED?
- Around the Orbit With TED Treatment
- Teprotumumab – Can It Change the Treatment of TED?
- Case Presentation: Treatment of TED
- Panel Discussion: Where Do We Go From Here?
Thyroid eye disease (TED) is an autoimmune disorder believed to result from the stimulation of several receptors located in the orbital fibroblasts. It is frequently misdiagnosed, due to both its heterogeneous clinical presentation and a failure on the part of clinicians to understand the relationship between TED and hyperthyroidism. Misdiagnosis can place patients at risk, as management of TED is most effective during the initial, active phase of the disease. However, differential diagnosis can be achieved with the assistance of imaging, and early treatment may limit disfigurement and reduce vision loss. Ophthalmologists, endocrinologists, neuro-ophthalmologists, oculoplastic surgeons, optometrists, and other health care professionals should be knowledgeable about the presentation of these patients, which includes patients with dry eye as well as conventional and new treatment options available for patients with TED. In this case-based program, expert faculty will discuss these treatment options, including teprotumumab—the first and only medical agent approved by the US Food and Drug Administration for the treatment of TED. The "Thyroid Eye Disease Forum" is a 3 city, live meeting series that aims to provide health care professionals with guidance on the appropriate management of patients with TED. The sessions will incorporate didactic presentations, clinical cases, as well as question & answer sessions to drill down deeper into the diagnosis and treatment of TED.
The intended audience for these activities are ophthalmologists, endocrinologists, neuro-ophthalmologists, oculoplastic surgeons, optometrists, and other health care professionals involved in the management of patients with TED.
Upon successful completion of these activities, participants should be better able to:
- Review the pathogenesis, patient risk factors, and nomenclature associated with TED.
- Recognize the heterogenous presentation of TED, ocular disorders with similar symptomatology, and the need for an extensive differential diagnosis.
- Assess procedures and modalities that aid in the early diagnosis of TED.
- Examine case presentations that provide diagnostic and management solutions that can improve the overall outcomes for patients with TED.
- Differentiate current medical and surgical treatments for TED, based on their efficacy, benefits, limitations, and ability to improve outcomes in both the active and chronic phase of the disease.
- Evaluate the efficacy and safety of insulin-like growth factor 1 receptor (IGF-1R) therapy and how it may be incorporated into practice, safely and effectively.
- Summarize the importance of a multidisciplinary team in managing patients with TED, referral to appropriate specialists, and need for patient education about the disease and its management.